Sign up to save your podcasts
Or
Share How Phio Pharmaceuticals Is Reawakening the Immune System to Fight Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How Phio Pharmaceuticals Is Reawakening the Immune System to Fight Cancer
As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we’re showcasing the innovative companies presenting at the DealFlow Discovery Conference and the executives behind them.
Today’s spotlight features Robert Bitterman, CEO & President of Phio Pharmaceuticals, who discusses how the company’s INTASYL™ RNA platform is engineered to reactivate immune cells directly within the tumor microenvironment — opening the door to safer, more targeted cancer therapies.
In this episode, Adam Torres interviews Robert Bitterman, CEO and President of Phio Pharmaceuticals, about the company’s mission to create new pathways toward a cancer-free future. Robert explains how Phio’s INTASYL™ platform uses targeted RNA technology to reactivate immune cells inside the tumor microenvironment, potentially offering a safer and more effective approach to treating cutaneous squamous cell carcinoma. He also shares early clinical data, the next steps toward pivotal trials, and why education and innovation remain at the heart of Phio’s work.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biopharmaceutical company whose proprietary INTASYL siRNA technology makes our bodies’ immune cells more effective in killing tumor cells. INTASYL is the only self-delivering siRNA technology focused on immuno-oncology therapeutics.
Phio was co-founded by a Nobel Laureate for discovery of RNAi. This discovery was leveraged to develop INTASYL, our broadly patented synthetic short interfering RNA (siRNA) drug technology. INTASYL is precisely designed to specifically silence targeted gene in the human body, causing our immune cells to be more effective in killing tumor cells.
Watch this episode on Youtube.
Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.
Apply to be a guest on our podcast:
https://missionmatters.lpages.co/podcastguest/
Visit our website:
https://missionmatters.com/
More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia
Learn more about your ad choices. Visit podcastchoices.com/adchoices
View all episodes
By Adam Torres
4.8
6767 ratings
As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we’re showcasing the innovative companies presenting at the DealFlow Discovery Conference and the executives behind them.
Today’s spotlight features Robert Bitterman, CEO & President of Phio Pharmaceuticals, who discusses how the company’s INTASYL™ RNA platform is engineered to reactivate immune cells directly within the tumor microenvironment — opening the door to safer, more targeted cancer therapies.
In this episode, Adam Torres interviews Robert Bitterman, CEO and President of Phio Pharmaceuticals, about the company’s mission to create new pathways toward a cancer-free future. Robert explains how Phio’s INTASYL™ platform uses targeted RNA technology to reactivate immune cells inside the tumor microenvironment, potentially offering a safer and more effective approach to treating cutaneous squamous cell carcinoma. He also shares early clinical data, the next steps toward pivotal trials, and why education and innovation remain at the heart of Phio’s work.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biopharmaceutical company whose proprietary INTASYL siRNA technology makes our bodies’ immune cells more effective in killing tumor cells. INTASYL is the only self-delivering siRNA technology focused on immuno-oncology therapeutics.
Phio was co-founded by a Nobel Laureate for discovery of RNAi. This discovery was leveraged to develop INTASYL, our broadly patented synthetic short interfering RNA (siRNA) drug technology. INTASYL is precisely designed to specifically silence targeted gene in the human body, causing our immune cells to be more effective in killing tumor cells.
Watch this episode on Youtube.
Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.
Apply to be a guest on our podcast:
https://missionmatters.lpages.co/podcastguest/
Visit our website:
https://missionmatters.com/
More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia
Learn more about your ad choices. Visit podcastchoices.com/adchoices
More shows like Mission Matters Business Podcast with Adam Torres
View all
Explain It to Me
7,861 Listeners
Mission Matters Innovation with Adam Torres
3 Listeners
Mission Matters Entertainment with Adam Torres
2 Listeners
Mission Matters Luxury with Adam Torres
0 Listeners
Mission Matters Money with Adam Torres
7 Listeners
Mission Matters Marketing with Adam Torres
2 Listeners
Mission Matters Startup Garage with Adam Torres
1 Listeners
Mission Matters Fitness with Adam Torres
1 Listeners